In his “No Mercy, No Malice” blog, entrepreneur and NYU Professor Scott Galloway looks at two innovations of the post-Covid era that promise to have profound effects on how we live: Ozempic and Artificial Intelligence. Dr. Gallow ingeniously uses the impact of Ozempic (aka GLP-1 drugs) to explain how AI is already impacting how CEOs are thinking about, and managing, their work forces.
He writes:
“If you want to understand how AI is reshaping business, picture it as the other massive innovation of our time: GLP-1 drugs. Both shed weight by suppressing cravings; both exacerbate existing inequities (aka the rich get richer) before generating wider prosperity; and both are having a greater impact than projected as early adopters are hesitant to admit they’re using.” To be specific, he suggests that recent tech and non-tech “layoffs are no longer a signal of economic conditions, but innovation.”
I found this article both fascinating and profound in its implications. You will be well served by spending a few minutes digesting Dr. Galloways thoughts, and warnings, about “Corporate Ozempic.”
You will not look at layoffs and hiring in the same way again, especially if you’re responsible for both.
